A detailed history of Dimensional Fund Advisors LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 792,423 shares of COGT stock, worth $7.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
792,423
Previous 930,297 14.82%
Holding current value
$7.05 Million
Previous $7.84 Million 9.13%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$8.24 - $11.48 $1.14 Million - $1.58 Million
-137,874 Reduced 14.82%
792,423 $8.56 Million
Q2 2024

Aug 09, 2024

SELL
$6.01 - $9.04 $2.79 Million - $4.19 Million
-463,901 Reduced 33.27%
930,297 $7.84 Million
Q1 2024

May 10, 2024

SELL
$4.38 - $9.02 $1.06 Million - $2.19 Million
-242,636 Reduced 14.82%
1,394,198 $9.37 Million
Q4 2023

Feb 07, 2024

BUY
$4.06 - $10.08 $232,000 - $576,001
57,143 Added 3.62%
1,636,834 $9.62 Million
Q3 2023

Nov 09, 2023

BUY
$9.69 - $13.34 $4.48 Million - $6.17 Million
462,345 Added 41.38%
1,579,691 $15.4 Million
Q2 2023

Aug 09, 2023

BUY
$9.85 - $13.24 $2.84 Million - $3.82 Million
288,384 Added 34.79%
1,117,346 $13.2 Million
Q1 2023

May 12, 2023

BUY
$10.04 - $15.5 $3.64 Million - $5.63 Million
362,943 Added 77.88%
828,962 $8.94 Million
Q4 2022

Feb 09, 2023

BUY
$10.65 - $14.84 $4.2 Million - $5.85 Million
394,009 Added 547.16%
466,019 $5.39 Million
Q3 2022

Nov 10, 2022

SELL
$9.39 - $16.99 $13,700 - $24,788
-1,459 Reduced 1.99%
72,010 $1.07 Million
Q2 2022

Aug 12, 2022

BUY
$3.92 - $9.73 $8,020 - $19,907
2,046 Added 2.86%
73,469 $662,000
Q1 2022

May 13, 2022

BUY
$5.31 - $8.7 $150,920 - $247,271
28,422 Added 66.1%
71,423 $535,000
Q4 2021

Feb 09, 2022

BUY
$7.51 - $10.81 $322,937 - $464,840
43,001 New
43,001 $369,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $585M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.